News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
7,397 ^JPY	-0.23%		+0.11%	+8.81%

Apr. 30	Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	CI
Apr. 25	Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30	CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	Apr. 25	CI
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	Apr. 23	AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	Apr. 19	AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	Apr. 19	AQ
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	Apr. 19	MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	Apr. 18	CI
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	Apr. 12	AQ
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	Mar. 28	CI
Final dividend	Mar. 27	FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	Mar. 21	CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 20	CI
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	Mar. 08	AQ
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	Mar. 07	MT
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	Mar. 06	AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 06	AQ
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06	MT
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	Mar. 05	AQ
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Summary

Filters